Amgen (NASDAQ:AMGN) Price Target Raised to $410.00

Amgen (NASDAQ:AMGN) had its price target boosted by Daiwa Securities Group from $370.00 to $410.00 in a report released on Tuesday,MarketScreener reports. The brokerage currently has an outperform rating on the medical research company’s stock.

Several other research firms have also weighed in on AMGN. The Goldman Sachs Group increased their target price on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. UBS Group upped their price target on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Scotiabank began coverage on shares of Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price objective for the company. Finally, Wells Fargo & Company upped their target price on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $354.04.

Amgen Price Performance

NASDAQ:AMGN opened at $366.20 on Tuesday. Amgen has a 52 week low of $261.43 and a 52 week high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a 50-day moving average of $336.68 and a 200-day moving average of $313.14. The company has a market capitalization of $197.19 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 3.75 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities research analysts anticipate that Amgen will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, February 13th. This is a boost from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is currently 66.90%.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares of the company’s stock, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.76% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Amgen

Several hedge funds and other institutional investors have recently made changes to their positions in AMGN. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its holdings in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen in the 4th quarter worth $26,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the second quarter valued at about $27,000. Finally, Evelyn Partners Investment Management LLP acquired a new position in Amgen during the 2nd quarter valued at about $32,000. 76.50% of the stock is owned by institutional investors.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.